Focused on the Future

Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential. Our product candidates are engineered to address specific therapeutic needs across ocular surface, anterior segment and posterior segment diseases, including the leading causes of blindness. With an aging population, there is a clear growing need for these types of innovative ocular therapies that may enhance the overall patient and physician experience.

Ocular's pipeline includes therapeutics for retina (preclinical - phase 1), glaucoma (phase 2), ocular disease (phase 2) and gene therapy (preclinical).

Caution: All pipeline product candidates in preclinical or clinical stage development are limited by law to investigational use only. This page is not intended to convey conclusions about efficacy or safety about any of these investigational products, and there is no guarantee that any will successfully complete development or gain FDA approval.